PT  - JOURNAL ARTICLE
AU  - Bowie, Cam
TI  - Modelling the effect of an improved trace and isolate system in the wake of a highly transmissible Covid-19 variant with potential vaccine escape
AID  - 10.1101/2021.06.07.21258451
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.07.21258451
4099  - http://medrxiv.org/content/early/2021/06/10/2021.06.07.21258451.short
4100  - http://medrxiv.org/content/early/2021/06/10/2021.06.07.21258451.full
AB  - Objective How helpful would a properly functioning find, test, trace, isolate and support (FTTIS) system be now in the UK with new Covid-19 infections at a low level and half the adult population immunised but with a highly transmissible variant becoming predominant?Design a dynamic causal model of Covid-19 supplied with the latest available empirical data is used to assess the impact of a new highly transmissible variant.Setting the United Kingdom.Participants a population based study.Interventions scenarios are used to explore a Covid-19 transmission rate 50% more and twice the current rate with or without a more effective FTTIS system.Main outcome measures incidence, death rate and reproductive ratioResults a small short third wave of infections occurs which does not occur if FTTIS effectiveness is improved from 25% to 30%.Conclusion a modest improvement in FTTIS would prevent a third wave caused by a highly transmissible virus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study does not require ethics approvalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDCM code and technical information available at https://www.fil.ion.ucl.ac.uk/spm/covid-19/. Data files found at https://www.fil.ion.ucl.ac.uk/spm/covid-19/dashboard/data/data.zip Code for scenarios obtained by request from cam.bowie1{at}gmail.com